Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kala Bio Inc (KALA)

Kala Bio Inc (KALA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,259
  • Shares Outstanding, K 2,816
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,200 K
  • 60-Month Beta -1.85
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.58
Trade KALA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -2.89
  • Number of Estimates 2
  • High Estimate -2.64
  • Low Estimate -3.14
  • Prior Year -6.99
  • Growth Rate Est. (year over year) +58.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.65 +2.83%
on 04/17/24
8.12 -15.79%
on 04/02/24
-0.69 (-9.19%)
since 03/15/24
3-Month
6.43 +6.35%
on 02/02/24
8.89 -23.08%
on 01/18/24
-2.16 (-24.02%)
since 01/17/24
52-Week
5.10 +34.08%
on 11/14/23
19.35 -64.67%
on 05/18/23
-9.83 (-58.98%)
since 04/17/23

Most Recent Stories

More News
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate

Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.

CRSP : 55.56 (-4.14%)
KALA : 6.84 (-0.17%)
ALLO : 3.51 (+0.29%)
DRMA : 0.2949 (+10.66%)
VYNE Gains on Preclinical Data for IPF Candidate

VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.

CRSP : 55.56 (-4.14%)
KALA : 6.84 (-0.17%)
ALLO : 3.51 (+0.29%)
VYNE : 2.40 (-0.83%)
Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag

Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.

CRSP : 55.56 (-4.14%)
MDGL : 228.34 (-1.99%)
KALA : 6.84 (-0.17%)
ALLO : 3.51 (+0.29%)
Gamida Cell (GMDA) Surges on FDA Approval for Omisirge

Gamida Cell's (GMDA) shares surge as it receives FDA approval for Omisirge, an allogeneic cell therapy for blood cancer patients.

CRSP : 55.56 (-4.14%)
KALA : 6.84 (-0.17%)
ALLO : 3.51 (+0.29%)
GMDA : 0.0327 (-18.25%)
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia

Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.

CRSP : 55.56 (-4.14%)
HGEN : 0.0002 (-84.62%)
KALA : 6.84 (-0.17%)
ALLO : 3.51 (+0.29%)
Alvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate

Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.

TEVA : 13.18 (+0.69%)
KALA : 6.84 (-0.17%)
ALLO : 3.51 (+0.29%)
ALVO : 12.80 (+0.55%)
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429

Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.

RGLS : 2.34 (-8.59%)
CRSP : 55.56 (-4.14%)
KALA : 6.84 (-0.17%)
ALLO : 3.51 (+0.29%)
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug

Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-onset type 1 diabetes.

CRSP : 55.56 (-4.14%)
KALA : 6.84 (-0.17%)
ALLO : 3.51 (+0.29%)
PBLA : 0.5160 (-1.71%)
Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News

Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.

MRNA : 103.44 (-0.34%)
IFRX : 1.2650 (-3.44%)
KALA : 6.84 (-0.17%)
KALA Up on Fast Track Designation to Lead Ocular Candidate

KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects.

NVO : 124.53 (+0.87%)
LGND : 78.87 (-1.31%)
KALA : 6.84 (-0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

KALA BIO is a clinical-stage biopharmaceutical company. It focused on the research, development and commercialization of therapies for rare and severe diseases of the eye. The company' s lead product candidate consists KPI-012. KALA BIO, formerly known as Kala Pharmaceuticals Inc., is based in ARLINGTON,...

See More

Key Turning Points

3rd Resistance Point 7.34
2nd Resistance Point 7.17
1st Resistance Point 7.00
Last Price 6.84
1st Support Level 6.66
2nd Support Level 6.49
3rd Support Level 6.32

See More

52-Week High 19.35
Fibonacci 61.8% 13.91
Fibonacci 50% 12.23
Fibonacci 38.2% 10.54
Last Price 6.84
52-Week Low 5.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar